-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Should You Be Adding Grand Pharmaceutical Group (HKG:512) To Your Watchlist Today?
Should You Be Adding Grand Pharmaceutical Group (HKG:512) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
In contrast to all that, many investors prefer to focus on companies like Grand Pharmaceutical Group (HKG:512), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
See our latest analysis for Grand Pharmaceutical Group
Grand Pharmaceutical Group's Earnings Per Share Are Growing
If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. That means EPS growth is considered a real positive by most successful long-term investors. Shareholders will be happy to know that Grand Pharmaceutical Group's EPS has grown 35% each year, compound, over three years. If the company can sustain that sort of growth, we'd expect shareholders to come away satisfied.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. On the revenue front, Grand Pharmaceutical Group has done well over the past year, growing revenue by 35% to HK$8.6b but EBIT margin figures were less stellar, seeing a decline over the last 12 months. So if EBIT margins can stabilize, this top-line growth should pay off for shareholders.
You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.
SEHK:512 Earnings and Revenue History August 9th 2022The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Grand Pharmaceutical Group's future EPS 100% free.
Are Grand Pharmaceutical Group Insiders Aligned With All Shareholders?
Insider interest in a company always sparks a bit of intrigue and many investors are on the lookout for companies where insiders are putting their money where their mouth is. This view is based on the possibility that stock purchases signal bullishness on behalf of the buyer. Of course, we can never be sure what insiders are thinking, we can only judge their actions.
Belief in the company remains high for insiders as there hasn't been a single share sold by the management or company board members. But the real excitement comes from the HK$711k that Executive Director Zhanqi Niu spent buying shares (at an average price of about HK$4.10). Strong buying like that could be a sign of opportunity.
On top of the insider buying, we can also see that Grand Pharmaceutical Group insiders own a large chunk of the company. In fact, they own 49% of the shares, making insiders a very influential shareholder group. Shareholders and speculators should be reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. This insider holding amounts to That level of investment from insiders is nothing to sneeze at.
Should You Add Grand Pharmaceutical Group To Your Watchlist?
If you believe that share price follows earnings per share you should definitely be delving further into Grand Pharmaceutical Group's strong EPS growth. Better still, insiders own a large chunk of the company and one has even been buying more shares. So it's fair to say that this stock may well deserve a spot on your watchlist. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Grand Pharmaceutical Group that you should be aware of.
Keen growth investors love to see insider buying. Thankfully, Grand Pharmaceutical Group isn't the only one. You can see a a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對於初學者來説,收購一家向投資者講述一個好故事的公司似乎是一個好主意(也是一個令人興奮的前景),即使它目前沒有收入和利潤的記錄。但正如彼得·林奇在華爾街上的一位“遠投幾乎永遠不會有回報。”一家虧損的公司還沒有用盈利來證明自己,最終外部資本的流入可能會枯竭。
與此形成鮮明對比的是,許多投資者更傾向於關注像大藥業集團(HKG:512),不僅有收入,而且有利潤。現在,這並不是説該公司提供了最好的投資機會,但盈利能力是商業成功的關鍵組成部分。
查看我們對大藥業集團的最新分析
大藥業集團每股收益不斷增長
如果一家公司能夠在足夠長的時間內保持每股收益(EPS)的增長,其股價最終應該會隨之而來。這意味着,大多數成功的長期投資者認為,每股收益的增長是一個真正的積極因素。股東們會很高興地知道,大藥業集團的每股收益在過去三年裏以每年35%的複合增長率增長。如果公司能夠保持這樣的增長,我們預計股東們會滿意地離開。
仔細考慮收入增長和息税前利潤(EBIT)利潤率有助於瞭解最近利潤增長的可持續性。在收入方面,大藥業集團在過去一年中表現良好,收入增長35%,至86億港元,但息税前利潤數據沒有那麼亮眼,過去12個月出現下降。因此,如果息税前利潤能夠企穩,這種營收增長應該會為股東帶來回報。
你可以在下面的圖表中看到該公司的收入和收益增長趨勢。點擊圖表查看確切的數字。
聯交所:512盈利及收入歷史2022年8月9日作為投資者,訣竅在於找到符合以下條件的公司要去在未來有好的表現,而不僅僅是在過去。雖然水晶球不存在,但你可以查看我們對大藥業集團未來每股收益100%免費的共識分析師預測的可視化。
大藥業集團內部人士是否與所有股東一致?
內部人對一家公司的興趣總是會引發一些陰謀,許多投資者都在尋找內部人把錢放在嘴邊的公司。這種觀點是基於這樣一種可能性,即購買股票代表買家發出看漲信號。當然,我們永遠無法確定內部人士在想什麼,我們只能判斷他們的行為。
內部人士對該公司的信心仍然很高,因為管理層或董事會成員沒有出售過一股股票。但真正令人興奮的是董事高管牛佔奇斥資71.1萬港元買入股票(平均價約4.10港元)。像這樣的強勁買入可能是機會的跡象。
除了內幕收購,我們還可以看到,大藥業集團內部人士持有該公司很大一部分股份。事實上,他們擁有49%的股份,使內部人士成為一個非常有影響力的股東羣體。股東和投機者應該對這種調整感到放心,因為它表明企業的運營將為股東的利益服務。這種內部人持股相當於來自內部人的投資水平,不容忽視。
你應該將大藥業集團添加到你的觀察名單中嗎?
如果你相信股價跟隨每股收益,你肯定應該進一步研究大藥業集團強勁的每股收益增長。更好的是,內部人士擁有該公司的很大一部分股份,其中一人甚至一直在購買更多股票。因此,公平地説,這隻股票很可能值得在你的觀察名單上佔有一席之地。別忘了,可能還會有風險。例如,我們已經確定大藥業集團的1個警告標誌這一點你應該知道。
熱衷於增長的投資者喜歡看到內幕收購。值得慶幸的是,大藥業集團並不是唯一一家。你可以在這裏看到它們的免費列表。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧